Aiming to continue expanding its global presence and promoting its new brand “Pulmogine,” HCmed Innovations participated at two main events held in China this month. AstraZeneca China invited HCmed to join the 2019 China International Import Expo, also known as the largest event of its kind in China, from Nov.5 to Nov.10. Similarly, HCmed also participated in the 2019 China Healthcare Summit from Nov.18 to Nov.20, in this occasion supported by its partnership with the I-Campus program of Wuxi International Life Science Innovation Park.
The China International Expo is an event that welcomes business groups, exhibitors and professional buyers across the world to explore the Chinese market. This year a vast number of healtcase companies participated in the expo with the intention of displaying their products to further tap into the local market.
On a different note, this year’s China Healthcare Summit was organized by BioCentury in Shanghai. The event focused on serving as a key stage for biomedical companies to gather and interact with investors. Besides providing a space for exhibitors, the event also included one-on-one symposiums, lectures, and forums for discussion.
During both events, HCmed had the opportunity to present its new brand “Pulmogine”. Pulmogine is a mesh nebulizer that is capable of delivering different types of medications, such as solutions, suspensions, biologics and high viscosity drugs. Moreover, it offers a customization platform that permits to tailor components to enhance drug delivery and adjust parameters to target specific requirements. HCmed emphasized that Pulmogine counts with other important features, including water-resistance, friendly usage, and portability, making it a top-quality device to be combined with high value therapeutic drugs.
To wrap up this year, HCmed is going to participate in the 2019 DDL Conference in Edinburgh from Dec.11 to Dec.13 as a platinum sponsor.